Shanghai Tasly Pharmaceutical Co., Ltd. announced that it will receive CNY 74,363,100 in an equity round of funding on April 20, 2018. The transaction will involve participation from existing investors Tasly Pharmaceutical Group Co., Ltd. (SHSE:600535) for CNY 55,000,000, Tianjin Tasly Enterprise Management Co., Ltd. for CNY 19,363,100 of which CNY 35,000,000 and CNY 1,842,100 respectively will be added to the registered capital of the company and remaining proceeds will go towards the capital reserve of the company. Post the closing of the transaction, the registered capital of the company will increase from CNY 953,861,420 to CNY 990,703,520 and the investors will continue to retain their existing stakes in the company. The company reported total assets of CNY 718,403,997.25, total liabilities of CNY 324,242,492.34, net assets of CNY 394,161,504.91, operating revenue of CNY 100,268,974.51, and net profit of CNY -71,176,693.13 for the year ended December 31, 2017.